Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2023-184634

Published: 2023

Journal Articles

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Xi Chen, Jieyu Xu, Haifeng Yu, Tao Lei, Cong Li, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6311.

https://doi.org/10.1182/blood-2023-189282

Published: 2023

Journal Articles

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Huixian HU, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6221.

https://doi.org/10.1182/blood-2023-184830

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Xi Chen, Yingying Chen, Tao Lei, Haifeng Yu, Cong Li, Yongwei Hong, Haiyan Yang

Blood (2023) 142 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2023-182685

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2023-184694

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study

Zhiming Li, Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu

Blood (2023) 142 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2023-178492

Published: 2023

Journal Articles

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

Wei Liu, Yunhong Huang, Haiyan Yang, Zhiming Li, Zhen Cai, Zhen Wang, Lihong Liu, Ye Guo, Ligen Liu, Rui Huang, Xu Ye, Lugui Qiu

Blood (2023) 142 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2023-177550

Published: 2023

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Jun Zhu, Yuqin Song, Ye Guo, Keshu Zhou, Wenyu Li, Yu Yang, Qingqing Cai, Zhao Wang, Haiyan Yang

Blood (2023) 142 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2023-189675

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Yuqin Song, Keshu Zhou, Hongmei Jing, Jianqiu Wu, Haiyan Yang, Yu Bai, Ke Fang, Ziyi Liu, Jun Zhu, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2023-185270

Published: 2023

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xinglu Zhou

Blood (2023) 142 (Supplement 1): 3139.

https://doi.org/10.1182/blood-2023-185241

Published: 2023

NARROW

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only